Evidence map›Paper›PMID 32661627›Full record

ArticleInternational urology and nephrology2020

Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients.

Baoxin Li, Xi Tian, Shuqin Guo, Mali Zhang, Jie Li, Na Zhai, He Wang, Yunliang Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Baoxin LiDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China.ORCID http://orcid.org/0000-0001-9901-8208
Xi TianDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China.
Shuqin GuoDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China.
Mali ZhangDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China.
Jie LiDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China.
Na ZhaiDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China.
He WangDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China.
Yunliang ZhangDepartment of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, China. nfmzyl@163.com.ORCID http://orcid.org/0000-0002-0511-1071
Baoding People's Hospital · CNGreat Wall Motors (China) · CN

Funding

Hebei province medical applicable technology tracking project G2019012Project of National Natural Science Foundation of China 81500644
6 · The paper itself

Abstract

purposeRenal inflammatory response is involved in the development and progression of diabetic kidney disease (DKD). We sought to evaluate pentraxin-3 (PTX3) and adropin variability as inflammatory markers among type 2 diabetes mellitus (T2DM) patients with different urinary albumin, and to examine if these factors assist in the early diagnosis of diabetic kidney disease.

methodsWe enrolled 447 T2DM patients and 100 healthy non-diabetic control subjects in this study. The patients with T2DM were divided into three groups based on their urinary albumin/creatinine ratio (UACR): the normoalbuminuric group (DM group, UACR < 30 mg/g); the microalbuminuric group (DKD1 group, 30 ≤ UACR ≤ 300 mg/g); the macroalbuminuric group (DKD2 group, UACR > 300 mg/g). The levels of PTX3 and adropin were determined by enzyme-linked immunosorbent assay (ELISA). Spearman correlation and multiple linear regression analysis were performed to determine the correlations among these inflammatory markers and other clinical parameters. Receiver operating characteristic (ROC) curves analysis was used to assess the diagnostic potential of PTX3 and adropin for DKD.

resultsCompared to non-diabetes, serum levels of PTX3 were distinctly elevated, whereas the adropin were significantly declined in diabetic patients (p < 0.05). Significantly higher levels of PTX3 and lower levels of adropin were seen in the macroalbuminuric patients compared with the microalbuminuric patients (p < 0.05). Multiple stepwise linear regression analysis showed that the control of hemoglobin A1c (HbA1c) and UACR were independent factors associated with PTX3 and adropin. In addition, ROC curves analysis showed PTX3 and adropin could be used to evaluate the early detect of DKD, further adropin might be a better marker than PTX3 in compliance with their veracity.

conclusionAs inflammatory markers, the diverse changes of pentraxin-3 and adropin showed that they may forecast the renal damage in diabetic patients in varying degrees and link with the pathogenesis of diabetic kidney disease.

Indexed as

AgedAlbuminuriaBiomarkersC-Reactive ProteinCross-Sectional StudiesDiabetes Mellitus, Type 2Diabetic NephropathiesEarly DiagnosisHumansInflammationIntercellular Signaling Peptides and ProteinsMiddle AgedPentraxinsSerum Amyloid P-ComponentBiomarkersC-Reactive ProteinEnho protein, humanIntercellular Signaling Peptides and ProteinsPentraxinsSerum Amyloid P-ComponentAdropinDiabetesInflammatory markersPentraxin-3Renal damage

Identifiers

PMID32661627
OpenAlexW3043309346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.